ACIP review of the hepatitis B birth dose vaccination remains a grave concern - Please read more here.

Site Search

You searched for "hepatitis D"

  • Worrying About Disease Progression

    Worrying about disease progression: Respondents explained how much they worry about the impact of their CHB on their health in the future, and how this impacts their peace of mind and anxiety levels. Findings: 55% worry about developing liver cancer. 48% fear they will live a shorter life. One participant said “Well, my family doctor was telling me that I have 25% of getting liver cancer. So, I kind of very worry about myself. However, with a child, I feel like this is really important for me to carry through my motherhood, you know, to raise the child.” Take action: Ask your doctor to screen you for liver cancer. Talk to your doctor about treatment options for reducing liver cancer risk. Find a safe space to talk about your worries. HepBCommunity is a free online community where people with hepatitis B share with each other and learn together.

    https://www.hepb.org/resources-and-support/patient-facing-infographics/worrying-about-disease-progression/
  • Should I get the hepatitis B vaccine if I have a chronic HBV infection or have recovered from a past infection?

    No. The hepatitis B vaccine is a preventive vaccine. People who have a current infection or have recovered from a past infection receive no benefit from the hepatitis B vaccine series, though there is no risk to receiving the series.  The hepatitis B vaccine is important for family members, sexual partners and close household contacts. Individuals should be tested and vaccinated if they do not have a current infection or have not recovered from a past infection.  Additional Resources:  Learn more about testing for hepatitis B Learn more about hepatitis B vaccination Find more Frequently Asked Questions here.  Page updated 02/09/2022

    https://www.hepb.org/what-is-hepatitis-b/faqs/should-i-get-the-hepatitis-b-vaccine-if-i-have-a-chronic-hbv-infection-or-have-recovered-from-a-past-infection/
  • Nucleoside Analogues’ Benefits in HBV Vary

    This informative article from Internal Medicine News, July 1, 2014, analyzes two studies from the July issue of Gastroenterology, and looks at the impact of antivirals on the incidence of liver cancer, the need for liver transplantation and the risk of death in chronic HBV patients.  The potency of the antiviral made a significant difference and supported current practice guidelines recommending the use of entecavir and tenofovir as first line drugs for the treatment of chronic HBV. Be sure to also read the accompanying editorial by Dr. George Papatheodoridis.  Internal Medicine News Digital Network, July 1, 2014, article written by DENISE NAPOLI. Nucleoside analogues are effective at preventing hepatocellular carcinoma in hepatitis B, but all are not equal when it comes to overall mortality and liver transplant, according to two new studies in the July issue of Gastroenterology. In the first study, Dr. Chun-Ying Wu of the National Yang-Ming University, in Taipei, Taiwan, and his colleagues examined the long-term protective effects of nucleoside analogue therapy among chronic hepatitis B patients (doi.org/10.1053/j.gastro.2014.03.048). They conducted a retrospective nationwide cohort study using data from Taiwan’s National Health Insurance Research Database, collecting records from 1997 through 2010 on patients with chronic hepatitis B. Click here to read Internal Medicine News article and editorial in its entirety. 

    http://www.hepb.org/blog/nucleoside-analogues-benefits-in-hbv-vary/
  • Rallying Call

    livercancerconnect.org   Welcome to the newly launched blog from Liver Cancer Connect, the Hepatitis B Foundation’s dedicated program on liver cancer. The blog will focus on issues that affect families facing liver cancer. On the recent World Cancer Day 2014, we ushered in the new year with both sobering news and some optimism. First the sobering news. The American Cancer Society recently reported1 that the number of new cases of liver cancer and the number of deaths due to this disease continue to increase. The rate of liver/bile duct cancer has risen by 3% to 4% per year and mortality by about 2% over the past 2 decades. In sharp contrast, the death rate for all cancers combined has been steadily declining over the same period and the number of new cases has decreased for most cancers. Liver cancer is the fifth most common cancer in the world, and the third leading cause of cancer-related deaths. In fact, every 30 seconds, one person in the world dies of liver cancer. Yet liver cancer is largely preventable! Eliminating the main risk factors for liver cancer — chronic hepatitis B and C infections and fatty liver disease — can stop the development of liver cancer. Chronic hepatitis B and C infections, which cause about 85% of liver cancers worldwide, are preventable and treatable. A safe vaccine against hepatitis B (the world’s first anti-cancer vaccine) has been available since 1986. And while a cure is not yet available, hepatitis B infections can be kept under control with effective treatments. There is no vaccine yet for hepatitis C, but it can be cured. And fatty liver disease can be prevented by maintaining a healthy weight and diet. Equally important in preventing liver cancer are screening and surveillance, which help to find the cancer early. Screening is the first test that a person undergoes to detect either an increased risk for liver cancer or the actual presence of the cancer. Surveillance refers to the regular monitoring for liver

    http://www.hepb.org/blog/rallying-call/
  • HBV Journal Review - February 2014

    HBF is pleased to connect our blog readers to Christine Kukka’s monthly HBV Journal Review that she writes for the HBV Advocate. The journal presents the
latest in hepatitis B research, treatment, and prevention from recent academic and medical journals. This month, the following topics are explored: Tests for Antigens and Drug-Resistant Virus Emerge as Valuable Diagnostic Tools Experts Issue a Report Card on Side Effects from Antivirals Experts Weigh in on Why They Prefer Either Antivirals or Interferon Doctors Explain Which Medical Guidelines They Follow, Or Ignore Truvada Effective in Lowering Viral Load in Young Adults with High Viral Load Hepatitis B Causes Most Liver Cancer Deaths in China Smoking Shortens Survival after Liver Cancer Surgery  HBV Journal Review February 1, 2014 Vol 11, no 2 by Christine M. Kukka Tests for Antigens and Drug-Resistant Virus Emerge as Valuable Diagnostic Tools Measuring the amount of hepatitis B surface antigen (HBsAg) in your bloodstream or conducting quick tests for drug-resistant hepatitis B virus (HBV) may soon be part of your office visit in the brave new molecular world of hepatitis B treatment. Doctors increasingly are measuring HBsAg levels to determine if treatment is needed or if current medications are working. HBsAg tests—along with measuring alanine aminotransferase (ALT) for signs of liver damage and HBV DNA for viral load—may become essential tools to assess hepatitis B progression or remission. HBsAg is the protein that makes up the outer covering of HBV. When a patient has a high viral load (and is positive for the hepatitis B "e" antigen—HBeAg), there are often large quantities of HBsAg circulating in the blood stream. When viral replication slows and HBeAg disappears, there can be lower quantities of HBsAg. But experts are learning that high HBsAg levels can increase cancer risk, even in HBeAg-negative patients, according to a study published in the journal Annales de Biologie Clinique. (1) As

    http://www.hepb.org/blog/hbv-journal-review-february-2014/
  • Tenofovir Alafenamide Shows Similar Anti-HBV Activity with Less Kidney Toxicity

    Great news from the 2013 AASLD Liver Meeting regarding a new, lower-dose formulation of Tenofovir for the treatment of hepatitis B From HIVandHepatitis.com Published Thursday, 21 November 2013 00:00Written by Liz Highleyman A new formulation of tenofovir that can be taken at lower doses demonstrated potent activity against hepatitis B virus (HBV) similar to that of the existing formulation in a 28-day study, but with less effect on kidney function, researchers reported at the 64thAASLD Liver Meeting this month in Washington, DC. Gilead Science's tenofovir disoproxil fumarate (TDF, brand name Viread) -- the currently marketed formulation -- is one of the most effective antiviral drugs for hepatitis B as well as one of the most widely used antiretrovirals for HIV. TDF is generally safe and well-tolerated, but it can cause kidney toxicity in susceptible individuals and is also associated with bone loss. A new pro-drug formulation known as tenofovir alafenamide (TAF, formerly GS-7340) produces 5-fold higher concentrations of active tenofovir diphosphate in lymphoid cells that harbor HIV, but is more stable in plasma and results in lower blood drug levels and systemic exposures than those seen with TDF. This allows for reduced dosing with potentially less detrimental effect on the kidneys and bones. Over the past year researchers have reported that a 10 mg dose of TAF is as effective against HIV as a 300 mg dose of TDF through 48 weeks in Phase 2 studies, but the former has less impact on markers of kidney function and bone mineral density. Read more details here. 

    http://www.hepb.org/blog/tenofovir-alafenamide-shows-similar-anti-hbv-activity-with-less-kidney-toxicity/
  • What You Need to Know About Hepatitis C and Liver Cancer

    The Hepatitis B Foundation’s Liver Cancer Webinar Series continues Wednesday, April 3rd.  HBF’s first webinar was overwhelmingly successful, so we hope you’ll join us next week for “Liver Cancer and Hepatitis C: What You Need to Know”, presented by leading hepatitis C expert, Douglas LaBrecque, MD. Dr. LaBrecque is the Professor of Medicine and Director of the Liver Service at the University of Iowa. He also served as Chief of GI and Hepatology at the Iowa City VA Hospital for 19 years. He has conducted extensive research on the development and treatment of hepatitis C, hepatitis B, and other liver diseases, including liver transplantation with more than 100 peer-reviewed manuscripts, three books, 22 book chapters and over 150 abstracts. Liver cancer is the third leading cause of cancer-related deaths and the seventh most common cancer worldwide. But the major causes of liver cancer— such as chronic hepatitis B or hepatitis C, and cirrhosis— are largely preventable. And treatments for liver cancer are available. Join The Hepatitis B Foundation’s webinar series to learn about the risk factors for liver cancer and the importance of liver cancer screening and surveillance. The expert presenters will describe currently available treatment options and clinical trials. These webinars are provided free of charge to help educate and raise liver cancer awareness. Liver Cancer and Hepatitis C: What You Need to Know webinar details: Presented by: Dr. Douglas LaBrecque Date: Wednesday, April 3, 2013 Time: 3 pmEST; 12 pmPST Click here to register Download the March 6th Webinar and listen to Hepatitis B and Liver Cancer: What You Need to Know, by Dr. Robert Gish.  For additional accurate, easy-to-understand information on liver cancer, visit the Hepatitis B Foundation’s dedicated website, www.LiverCancerConnect.org.

    http://www.hepb.org/blog/what-you-need-to-know-about-hepatitis-c-and-liver-cancer/
  • Free Newsletters

    The Hepatitis B Foundation has two ways for you to keep up on our news! B Informed, the Hepatitis B Foundation’s free print newsletter, which is published twice a year, and B News, our email newsletter, which is published monthly. B Informed is available to read online, in print (U.S. addresses only) or download as a PDF. To subscribe, click here. You can choose: Print: If you reside in the U.S., you can subscribe to receive the print version by sending your address to info@hepb.org. Download: The latest issue of B Informed (Fall/Winter 2022) is posted here and the archive is here.   B News, our monthly enewsletter, provides research updates, information on public health initiatives and other Foundation news. To subscribe, click here. You can read recent issues of B News by clicking on the months listed. May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 September 2021 August 2021 July 2021 June 2021 May 2021 April 2021 March 2021 February 2021 January 2021 December 2020 November 2020 October 2020 September 2020 August 2020 July 2020 June 2020 May 2020 April 2020

    https://www.hepb.org/news-and-events/free-newsletters/
  • Annual Reports

    The Hepatitis B Foundation values your support and takes seriously our responsibility to be good stewards of your contributions. Click on the links below to view our Annual Reports which detail our research, outreach, public health and advocacy accomplishments for each year. Hepatitis B Foundation (HBF) considers first and foremost its mission in serving its constituents in all decisions, including whether to enter into a relationship with a funder or partner. You can click here to view our corporate ethics policy for support from commercial organizations. Annual Report 2022 Annual Report 2021 Annual Report 2020 Annual Report 2019 Annual Report 2018 Annual Report 2017 Annual Report 2016 Annual Report 2015 Annual Report 2014 Annual Report 2013 Annual Report 2012 Annual Report 2011

    https://www.hepb.org/about-us/annual-reports/
  • College Internship Program

    The Hepatitis B Foundation recruits outstanding college students for its College Summer Research Internship Program at our headquarters in Doylestown, Pa. (24 miles north of Center City, Philadelphia), a program started more than 20 years ago. Interns work with professional scientists from the Hepatitis B Foundation and its research arm, the Baruch S. Blumberg Institute. Valuable mentoring and supervision of individual projects is provided for each student. At the conclusion of the summer, interns present their projects to the faculty in a special seminar. The Summer Internship Program is supported by a grant from the Pennsylvania Department of Health and funding from other foundations, organizations and private individuals. This is a 10-week summer program scheduled for June 5 to Aug. 11, 2023. Students entering their junior or senior year of college in the Fall of 2023 are eligible to apply. Housing is the responsibility of the student. The deadline for applications is Feb. 6, 2023. Decisions will be made by April 28.  Job Description and Application Information Objectives of the Student Research Intern Program  The Hepatitis B Foundation’s College Internship provides a unique opportunity for college students in their junior or senior year who are considering graduate school, medical school, or industrial research careers, to spend 10 weeks in an innovative and educational program. By pairing the students with scientific research professionals, they are able to gain firsthand experience in research, other scholarly activities.  This unique experience allows participants the opportunity to gain a personal perspective on the entire scientific process: from formulating and testing hypotheses, to working with an advisor in a state-of-the-art research laboratory.  Areas of research activity could include translational therapeutics, experimental molecular biology and virology, biomarker discovery, and medicinal and computational chemistry. Since the HBF operates a biotechnology business incubator with 40+ small biotech companies, it also is possible for students to observe, and in some cases, work within these entrepreneurial startups. Expectations of the Student Research Intern This is a 10-week program that will run June 5 to Aug. 11, 2023. Students will be required to arrange their own housing and transportation to and from the research center. Interns are expected to participate in faculty supervised research projects as well as other scholarly activities at the Center, including attendance at seminars from professional scientists and research discussion groups.   At the end of the program, students are required to prepare a project abstract summarizing their work and present their data to their peers and to HBF/BSBI faculty and staff.    Application Process To apply, please send the following to interns@hepb.org: A cover letter stating student’s reasons for interest in the program as well as their housing plans, A current resume and Two letters of recommendation that include email contact information for individuals who can comment on the applicant’s scientific potential. Stipends are available for qualified candidates. Only complete applications will be considered for the program. The deadline for this year’s program is Feb. 6. Click here for a printable version of the job description and application information.  For information about the program, contact: Hepatitis B Foundation Montana McAlorum: montana.mcalorum@bblumberg.org Education Programs 215-489-4900interns@hepb.org    

    https://www.hepb.org/research-and-programs/education-and-training/college-internship-program/